Chapter 2 The Pre-Travel Consultation
Interactions among Travel Vaccines & Drugs
INTERACTIONS AMONG TRAVEL VACCINES & DRUGS
Vaccines and medications are prescribed frequently in pre-travel consultations, and potential interactions between vaccines and medications, including those already taken by the traveler, must be considered. Although a comprehensive list of interactions is beyond the scope of this section, some of the more serious interactions of commonly used travel-related vaccines and medications are discussed here.
INTERACTIONS BETWEEN VACCINES
In general, concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. This observation has given rise to the recommendation that live-virus vaccines should be administered the same day or ≥4 weeks apart. If the 4-week span is not achievable, the second vaccine may be administered sooner to afford some protection, but it should be readministered ≥4 weeks later if the traveler is at continued risk. A study examining concurrent administration of the yellow fever vaccine with the measles-mumps-rubella (MMR) vaccine in 12-month-old children showed slightly reduced immunogenicity to yellow fever and mumps components, compared with responses following separate vaccination with MMR and yellow fever vaccines 30 days apart. The clinical significance of this finding is uncertain. Similarly, a single study suggested that in adults, concomitant administration of the 13-valent pneumococcal conjugate vaccine with the trivalent inactivated influenza vaccine results in lower immunogenicity to the PCV13 components. However, the clinical significance of this observation is uncertain, as responses still met FDA criteria of noninferiority. In infants given PCV13 and inactivated influenza vaccine concomitantly, the risk of fever and febrile seizure is slightly increased. However, this risk must be weighed against the need for both vaccines before travel and the time available to separate them.
INTERACTIONS BETWEEN TRAVEL VACCINES AND DRUGS
Oral Typhoid Vaccine
Live attenuated vaccines should generally be avoided in immunocompromised travelers, including those who are taking immunomodulators, calcineurin inhibitors, cytotoxic agents, antimetabolites, and high-dose steroids (see Table 8-08).
Antimicrobial agents may be active against the vaccine strain in the oral typhoid vaccine and may prevent an adequate immune response to the vaccine. Therefore, oral typhoid vaccine should not be given to people taking antibacterial agents. Vaccination with oral typhoid vaccine should be delayed for >72 hours after the administration of any such agent. Parenteral typhoid vaccine may be a more appropriate choice for these people.
Chloroquine and atovaquone-proguanil at doses used for malaria chemoprophylaxis may be given concurrently with the oral typhoid vaccine.
Concomitant use of chloroquine may reduce the antibody response to intradermal rabies vaccine administered for preexposure vaccination. The intramuscular route should be used for people taking chloroquine concurrently. (Currently, intradermal administration of rabies vaccine is not approved in the United States.)
INTERACTIONS BETWEEN ANTIMALARIALS AND SELECTED OTHER DRUGS
This section describes some of the more commonly encountered drug interactions. Any time a new medication is prescribed, clinicians should check for any interactions and inform the traveler of the potential risk.
Mefloquine may interact with several categories of drugs, including other antimalarial drugs, drugs that alter cardiac conduction, and anticonvulsants. Mefloquine is associated with increased toxicities of the antimalarial drug lumefantrine (available in the United States in fixed combination to treat people with uncomplicated Plasmodium falciparum malaria), potentially causing fatal prolongation of the QTc interval. Lumefantrine should therefore be avoided or used with caution in patients taking mefloquine prophylaxis. Although no conclusive data are available with regard to coadministration of mefloquine and other drugs that may affect cardiac conduction, mefloquine should be used with caution or avoided in patients taking antiarrhythmic or β-blocking agents, calcium-channel blockers, antihistamines, H1-blocking agents, tricyclic antidepressants, or phenothiazines. In general, mefloquine should also be avoided in travelers with a history of seizures. Mefloquine may also lower plasma levels of a number of anticonvulsants, such as valproic acid, carbamazepine, phenobarbital, and phenytoin; concurrent use of mefloquine with these agents should be avoided. Mefloquine can also lead to increased levels of calcineurin inhibitors and mTOR inhibitors (tacrolimus, cyclosporine A, and sirolimus) (see Table 8-10). Potent CYP3A4 inhibitors such as macrolides (clarithromycin, erythromycin), azole antifungals (ketoconazole, voriconazole, and itraconazole), antiretroviral protease inhibitors (ritonavir, lopinavir, darunavir, atazanavir), and cobicistat (available in a combination with elvitegravir) may increase the levels of mefloquine, increasing the risk for QT prolongation. CYP3A4 inducers such as efavirenz, nevirapine, etravirine, rifampin, and rifabutin may reduce plasma concentrations of mefloquine, and concurrent use should be avoided. Concurrent use of mefloquine with the new direct-acting protease inhibitors boceprevir and telaprevir used to treat hepatitis C should also be avoided.
Chloroquine may increase risk of prolonged QTc interval when given with other QT-prolonging agents (such as sotalol, amiodarone, and lumefantrine), and the combination should be avoided. The antiretroviral rilpivirine has also been shown to prolong QTc, and coadministration should be avoided. Chloroquine inhibits CYP2D6; when given concomitantly with substrates of this enzyme (such as metoprolol, propranolol, fluoxetine, paroxetine, flecainide), increased monitoring for side effects may be warranted. Chloroquine absorption may be reduced by antacids or kaolin; ≥4 hours should elapse between doses of these medications. Concomitant use of cimetidine and chloroquine should be avoided, as cimetidine can inhibit the metabolism of chloroquine and may increase drug levels. CYP3A4 inhibitors such as ritonavir, ketoconazole, and erythromycin may also increase chloroquine levels, and concomitant use should be avoided. Chloroquine inhibits bioavailability of ampicillin, and 2 hours should elapse between doses. Chloroquine is also reported to decrease the bioavailability of ciprofloxacin and methotrexate. Chloroquine may increase digoxin levels; increased digoxin monitoring is warranted. Use of chloroquine could possibly also lead to increased levels of calcineurin inhibitors and should be used with caution.
Tetracycline, rifampin, and rifabutin may reduce plasma concentrations of atovaquone and should not be used concurrently with atovaquone-proguanil. Metoclopramide may reduce bioavailability of atovaquone; unless no other antiemetics are available, this antiemetic should not be used to treat the vomiting that may accompany use of atovaquone at treatment doses. Atovaquone-proguanil should not be used with other medications that contain proguanil. Patients on anticoagulants may need to reduce their anticoagulant dose or monitor their prothrombin time more closely while taking atovaquone-proguanil, although coadministration of these drugs is not contraindicated. Atovaquone-proguanil may interact with the antiretroviral protease inhibitors ritonavir, darunavir, atazanavir, indinavir, and lopinavir, in addition to the nonnucleoside reverse transcriptase inhibitors nevirapine, etravirine, and efavirenz. Despite the potential for interactions, atovaquone-proguanil is well tolerated in most patients receiving these antivirals and is the preferred antimalarial for short-term travel. Cimetidine and fluvoxamine interfere with the metabolism of proguanil and should therefore be avoided.
Phenytoin, carbamazepine, and barbiturates may decrease the half-life of doxycycline. Patients on anticoagulants may need to reduce their anticoagulant dose while taking doxycycline because of its ability to depress plasma prothrombin activity. Absorption of tetracyclines may be impaired by bismuth subsalicylate, preparations containing iron, and antacids containing calcium, magnesium, or aluminum; these preparations should not be taken within 3 hours of taking doxycycline. Doxycycline may interfere with the bactericidal activity of penicillin, so these drugs, in general, should not be taken together. Doxycycline has no known interaction with antiretroviral agents, but concurrent use may lead to increased levels of calcineurin inhibitors and mTOR inhibitors (sirolimus).
INTERACTIONS WITH DRUGS FOR TREATMENT OF TRAVELERS' DIARRHEA
Increase in the international normalized ratio has been reported when levofloxacin and warfarin are used concurrently. Concurrent administration of ciprofloxacin and antacids that contain magnesium or aluminum hydroxide may reduce bioavailability of ciprofloxacin. Ciprofloxacin decreases clearance of theophylline and caffeine; theophylline levels should be monitored when ciprofloxacin is used concurrently. Ciprofloxacin and other fluoroquinolones should not be used with tizanidine. Sildenafil should not be used in patients on ciprofloxacin, as concomitant use is associated with increased rates of adverse effects. Fluoroquinolones have no known interaction with antiretroviral agents, but concurrent use may increase levels of calcineurin inhibitors and fluoroquinolone levels, and use should reflect renal function.
Close monitoring for side effects of azithromycin is recommended when azithromycin is used with nelfinavir. Increased anticoagulant effects have been noted when azithromycin is used with warfarin; monitoring prothrombin time is recommended for people taking these drugs concomitantly. Additive QTc prolongation may occur when azithromycin is used with the antimalarial artemether, and concomitant therapy should be avoided. Drug interactions have been reported with macrolides and antiretroviral protease inhibitors, as well as efavirenz and nevirapine, and can increase risk of QTc prolongation, though a short treatment course is not contraindicated for those without an underlying cardiac abnormality. Concurrent use with macrolides may lead to increased levels of calcineurin inhibitors.
Rifaximin is not absorbed in appreciable amounts by intact bowel, and no clinically significant drug interactions have been reported to date with rifaximin.
INTERACTIONS WITH DRUGS USED FOR TRAVEL TO HIGH ALTITUDES
Acetazolamide produces alkaline urine that can increase the rate of excretion of barbiturates and salicylates and may potentiate salicylate toxicity, particularly if taking a high dose of aspirin. Decreased excretion of dextroamphetamine, anticholinergics, mecamylamine, ephedrine, mexiletine, or quinidine may also occur. Hypokalemia caused by corticosteroids may be potentiated by concurrent use of acetazolamide. Acetazolamide should not be given to patients taking the anticonvulsant topiramate, as concurrent use is associated with increased toxicity. Increased monitoring of cyclosporine, tacrolimus, and sirolimus is warranted if these drugs are given with acetazolamide. Concurrent administration of metformin and acetazolamide should be done with caution as there may be an additive risk for lactic acidosis. Acetaminophen and diclofenac sodium form complex bonds with acetazolamide in the stomach’s acidic environment, impairing absorption. These agents should not be taken within 30 minutes of acetazolamide.
Dexamethasone interacts with multiple classes of drugs. Using this drug to treat altitude illness may, however, be life-saving. Interactions may occur with dexamethasone and the following drugs and drug classes: macrolide antibiotics, anticholinesterases, anticoagulants, hypoglycemic agents, isoniazid, digitalis preparations, oral contraceptives, and phenytoin.
DRUG INTERACTIONS IN PATIENTS ON HIV MEDICATIONS
Patients with HIV can be a challenge in the pre-travel consultation (See Chapter 8, Immunocompromised Travelers). A recent study in Europe showed that as many as 29% of HIV-positive travelers do not disclose their disease and medication status when seeking pre-travel advice. Antiretroviral medications have multiple drug interactions, especially through activation or inhibition of CYP3A4 and CYP2D6. There are several reports of antimalarial treatment failure and prophylaxis failure in patients on protease inhibitors and both nucleoside or nonnucleoside reverse transcriptase inhibitors. A number of the potential interactions are listed above, and 2 excellent resources for HIV medication interactions can be found at www.hiv-druginteractions.org and at www.aidsinfo.nih.gov.
- Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, Legros F. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J. 2009;8:289.
- Frenck RW Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012 Aug;19(8):1296–303.
- Hoey LL, Lake KD. Does ciprofloxacin interact with cyclosporine? Ann Pharmacother. 1994 Jan;28(1):93–6.
- Horowitz H, Carbonaro CA. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis. 1992 Dec;166(6):1462–4.
- Jabeen E, Qureshi R, Shah A. Interaction of antihypertensive acetazolamide with nonsteroidal anti-inflammatory drugs. J Photochem Photobiol B. 2013 Aug 5;125:155–63.
- Kolawole JA, Mustapha A, Abdul-Aguye I, Ochekpe N, Taylor RB. Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients. J Pharm Biomed Anal. 1999 Sep;20(5):737–43.
- Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ Jr. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis. 1997 Apr;175(4):871–5.
- Nascimento Silva JR, Camacho LA, Siqueira MM, FreireMde S, Castro YP, Maia Mde L, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011 Aug 26;29(37):6327–34.
- Nielsen US, Jensen-Fangel S, Pedersen G, Lohse N, Pedersen C, Kronborg G, et al. Travelling with HIV: a cross sectional analysis of Danish HIV-infected patients. Travel Med Infect Dis. 2014 Jan–Feb;12(1):72–8.
- Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, Sumner JW, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med. 1986 Jan 30;314(5):280–4.
- Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther. 2005 Jun;30(3):285–90.
- Uriel A, Lewthwaite P. Malaria therapy in HIV: drug interactions between nevirapine and quinine. Int J STD AIDS. 2011 Dec;22(12):768.
- Page created: July 10, 2015
- Page last updated: July 10, 2015
- Page last reviewed: July 10, 2015
- Content source: